chk2 t68p (Cell Signaling Technology Inc)

Cell Signaling Technology Inc is a verified supplier

Cell Signaling Technology Inc manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Cell Signaling Technology Inc chk2 t68p
Chk2 T68p, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+chk2/us12594293-489-17-23
Average 86 stars, based on 1 article reviews

chk2 t68p - by Bioz Stars, 2026-10

86/100 stars

Images

other:

Article Title: DNA damaging agents boost the transcription of endothelin A receptor in high-grade serous ovarian cancer.
Article Snippet: The following primary ab were adopted: anti-ETAR (1:5000, cat. no. PA3-065, Invitrogen); anti-γH2A.X (phospho-gammaH2A.X Ser-139) (1:1000, cat. no. 2577, Cell Signalling); anti-pATR (Ser428) (1:1000, cat. no. 2853, Cell Signalling); anti-ATR (1:1000; cat. no. 2790; Cell Signalling); anti-pATM (Ser1981) (D25E5) (1:1000, cat. no. 13050, Cell Signalling); anti-ATM (D2E2) (1:1000, cat. no. 2873, Cell Signalling); anti-pCHK1 (Ser345) (133D3) (1:1000, cat. no. 2348, Cell Signalling); anti-CHK1 (2G1D5) (1:1000, cat. no. 2360, Cell Signalling); anti-pCHK2 (T68) (C13C1) (1:1000, cat. no. 2197, Cell Signalling); anti-CHK2 (1:1000, cat. no. 2662, Cell Signalling); anti-pSTAT3 (Y705) (D3A7) (1:1000; cat. no. 9145, Cell Signalling); anti-STAT3 (D3Z2G) (1:1000, cat. no. 12640, Cell Signalling); anti-caspase 3 (D3R6Y) (1:1000, cat. no. 142200, Cell Signalling); anti-cleaved-caspase 3 (D175) (1:1000, cat. no. 9661, Cell Signalling); anti-cleaved-PARP (Asp 214) (1:1000, cat. no. 9541, Cell Signalling); AR TIC LE IN PR ES S anti-tubulin (DM1A) (1:200, cat. no. sc-32293, Santa Cruz Biotechnology) and anti-β-actin (AC-15) (1:5000, cat. no. 1978, Sigma-Aldrich).

Article Title: GATOR1 complex controls cisplatin sensitivity
Article Snippet: Anti-NPRL2 (37344), anti-CTR1 (13086), anti-phospho-p70 S6 kinase (Thr389) (9206), anti-p70 S6 kinase (9202), anti-p4EBP1 (Thr37/46) (2855), anti-4EBP1 (9452), anti-pTFEB (Ser211) (37681), anti-TFEB (37785), anti-pULK1 (Ser757) (14202), anti-ULK1 (8054), anti-pS6 (Ser 235/236) (2211), anti-S6 (2317), anti-p62 (8025), anti-phospho-histone-H2AX Ser139/Tyr142 (5438), anti-PARP1 (9542), anti-pAKT Ser473 (4060), anti-AKT (4619), anti-pAMPKα (Thr172) (2535), anti-AMPKα (5831), anti-phospho-p53 (Ser15) (9284), anti-p53 (2524), anti-pATM S1981 (4526), anti-ATM (2873), anti-ATR (2790), anti-pCHK1 (S345) (2341), anti-CHK1 (2360), anti-pCHK2 (Thr68) (2661), anti-CHK2 (2662), anti-p21 (2946), anti-LC3B (2775), anti-caspase 3 (9662), anti-GAPDH (2118), anti-vinculin (18799) were from Cell Signaling Technology.

Article Title: Aptamer-functionalized exosomes combined with doxorubicin suppress GBM progression and enhance chemoradiosensitivity by promoting pyroptosis
Article Snippet: The following primary antibodies were used under conditions specified by the manufacturers’ protocols: anti-GAPDH (Sigma, AF0911, 1:2000), anti-β-actin (Boster, BM0627, 1:2000), anti-53BP1 (CST, 4937, 1:500), anti-pATM (Ser1981) (CST, 5883, 1:500), anti-ATM (CST, 2873, 1:1000), anti-EGFR (CST, 4267, 1:1000), anti-pEGFR (tyr1038) (CST, 3777, 1:1000), anti-pChk2 (T68) (CST, 2661, 1:500), anti-Chk2 (CST, 2662, 1:500), anti-pH2A.X (S139) (CST, 9718, 1:1000), anti-cleaved-caspase-1 (tyr1038) (GeneTex, GTX133447, 1:500), anti-GSDMD (Abcam, AB210070 , 1:1000), anti-N-GSDMD (ABclonal, A22523, 1:500), anti-caspase-1 (Abcam, AB207802 , 1:1000), anti-NLRP3 (ABclonal, A5652, 1:1000), anti-caspase-3 (abcam, ab32351, 1:2000), anti-GSDME (abcam, ab215191, 1:2000), anti-CD63 (Abcam, AB217345 , 1:1000), anti-TSG101 (Abcam, AB125001 , 1:5000), anti-calnexin (Abcam, ab22595, 1:1000), and anti-CD81 (Santa Cruz Biotechnology, BS70675, 1:500).

Article Title: Aptamer-functionalized exosomes combined with doxorubicin suppress GBM progression and enhance chemoradiosensitivity by promoting pyroptosis
Article Snippet: The following primary antibodies were used under conditions specified by the manufacturers’ protocols: anti-GAPDH (Sigma, AF0911, 1:2000), anti-β-actin (Boster, BM0627, 1:2000), anti-53BP1 (CST, 4937, 1:500), anti-pATM (Ser1981) (CST, 5883, 1:500), antiATM (CST, 2873, 1:1000), anti-EGFR (CST, 4267, 1:1000), anti-pEGFR (tyr1038) (CST, 3777, 1:1000), anti-pChk2 (T68) (CST, 2661, 1:500), anti-Chk2 (CST, 2662, 1:500), anti-pH2A.X (S139) (CST, 9718, 1:1000), anti-cleaved-caspase-1 (tyr1038) (GeneTex, GTX133447, 1:500), antiGSDMD (Abcam, AB210070, 1:1000), anti-N-GSDMD (ABclonal, A22523, 1:500), anti-caspase-1 (Abcam, AB207802, 1:1000), antiNLRP3 (ABclonal, A5652, 1:1000), anti-caspase-3 (abcam, ab32351, 1:2000), anti-GSDME (abcam, ab215191, 1:2000), anti-CD63 (Abcam, AB217345, 1:1000), anti-TSG101 (Abcam, AB125001, 1:5000), anticalnexin (Abcam, ab22595, 1:1000), and anti-CD81 (Santa Cruz Biotechnology, BS70675, 1:500).

Article Title: PRMT5 is Frequently Upregulated and a Potential Therapeutic Target in MTAP-deficient Malignant Peripheral Nerve Sheath Tumors
Article Snippet: Primary antibodies were applied accordingly: Anti-PRMT5 (Sigma, cat. #07-405, RRID: AB_310589, 1:1000), anti-β-actin (Santa Cruz Biotechnology, cat# sc-47778, RRID:AB_626632, 1:200), anti-MTAP (Proteintech, cat. #11475-1-AP, RRID:AB_2147094, 1:2000), anti-p16/Ink4a (Proteintech, cat# 10883-1-AP, RRID:AB_2078303, 1:1000), anti-SDMA (Cell Signaling Technology, cat# 13222, RRID:AB_2714013, 1:2000), anti-H4R3me2s (Abcam, cat# ab5823, RRID:AB_10562795, 1:2000), anti-phospho-Histone H2A.X(Ser139) (Millipore, cat# 05-636, RRID:AB_309864, 1:200), anti-phospho-CHK1 (Cell Signaling Technology, cat# 2348, RRID:AB_331212, 1:1000), anti-CHK1 (Cell Signaling Technology, cat# 2360, RRID:AB_2080320, 1:1000), anti-phospho-CHK2 (Cell Signaling Technology, cat# 2197, RRID:AB_2080501, 1:1000), anti-CHK2 (Cell Signaling Technology, cat# 6334, RRID:AB_11178526, 1:1000), anti-RPA32 (Santa Cruz Biotechnology, cat# sc-56770, RRID:AB_785534, 1:200), anti-Rad51 (Cell Signaling Technology, cat# 8875, RRID:AB_2721109, 1:1000), anti-Ku70 (Santa Cruz Biotechnology, cat# sc-17789, RRID:AB_628454, 1:1000) and anti-Ku80 (Cell Signaling Technology, cat# 2753, RRID:AB_2257526, 1:1000).

Article Title: GATOR1 complex controls cisplatin sensitivity.
Article Snippet: Anti-NPRL2 (37344), anti-CTR1 (13086), anti-phospho-p70 S6 kinase (Thr389) (9206), anti-p70 S6 kinase (9202), anti-p4EBP1 (Thr37/46) (2855), anti4EBP1 (9452), anti-pTFEB (Ser211) (37681), anti-TFEB (37785), anti-pULK1 (Ser757) (14202), anti-ULK1 (8054), anti-pS6 (Ser 235/236) (2211), anti-S6 (2317), anti-p62 (8025), anti-phosphohistone-H2AX Ser139/Tyr142 (5438), anti-PARP1 (9542), anti-pAKT Ser473 (4060), anti-AKT (4619), anti-pAMPK (Thr172) (2535), anti-AMPKanti-phospho-p53 (Ser15) (9284), anti-p53 (2524), anti-pATM S1981 (4526), anti-ATM (2873), anti-ATR (2790), anti-pCHK1 (S345) (2341), anti-CHK1 (2360), anti-pCHK2 (Thr68) (2661), anti-CHK2 (2662), anti-p21 (2946), anti-LC3B (2775), anti-caspase 3 (9662), anti-GAPDH (2118), anti-vinculin (18799) were from Cell Signaling Technology.

Western Blot:

Article Title: Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer.
Article Snippet: .. The following antibodies were used for western blot analysis: anti-p-ATR (S428) (1:1000; 2853, Cell Signaling Technology, MA, USA), anti-ATR (1:1000; 13934, Cell Signaling Technology), anti-p-CHK1 (S345) (1:1000; 2348, Cell Signaling Technology), anti-CHK1 (1:1000; ab40866, Abcam, Cambridge, UK), anti-ATRIP (1:1000; 2737, Cell Signaling Technology), anti-p-ATM (S1981) (1:1000; 13050, Cell Signaling Technology), anti-ATM (1:1000; 2873, Cell Signaling Technology), anti-p-CHK2 (T68) (1:1000; 2197, Cell Signaling Technology), anti-CHK2 (1:1000; 6334, Cell Signaling Technology), anti-γ-H2AX (1:5000; AP0687, ABclonal, Wuhan, China), anti-β-actin (1:4000; A5316, Sigma-Aldrich). .. The following antibodies were used for IF analysis: anti-p-ATR (S428) (1:100; AP0676, ABclonal), anti-ATR (1:200; ab313435, Abcam), anti-pCHK1 (S345) (1:50; 2348, Cell Signaling Technology), anti-CHK1 (1:200; ab40866, Abcam), anti-γ-H2AX (1:50; AP0687, ABclonal).

Article Title: Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer
Article Snippet: .. The following antibodies were used for western blot analysis: anti-p-ATR (S428) (1:1000; 2853, Cell Signaling Technology, MA, USA), anti-ATR (1:1000; 13934, Cell Signaling Technology), anti-p-CHK1 (S345) (1:1000; 2348, Cell Signaling Technology), anti-CHK1 (1:1000; ab40866, Abcam, Cambridge, UK), anti-ATRIP (1:1000; 2737, Cell Signaling Technology), anti-p-ATM (S1981) (1:1000; 13050, Cell Signaling Technology), anti-ATM (1:1000; 2873, Cell Signaling Technology), anti-p-CHK2 (T68) (1:1000; 2197, Cell Signaling Technology), anti-CHK2 (1:1000; 6334, Cell Signaling Technology), anti-γ-H2AX (1:5000; AP0687, ABclonal, Wuhan, China), anti-β-actin (1:4000; A5316, Sigma-Aldrich). .. The following antibodies were used for IF analysis: anti-p-ATR (S428) (1:100; AP0676, ABclonal), anti-ATR (1:200; ab313435, Abcam), anti-p-CHK1 (S345) (1:50; 2348, Cell Signaling Technology), anti-CHK1 (1:200; ab40866, Abcam), anti-γ-H2AX (1:50; AP0687, ABclonal).

Review

chk2 t68p (Cell Signaling Technology Inc)

Structured Review

Images

Related Articles

other:

Western Blot:

Similar Products

Image Search Results